Cartesian Therapeutics
NEWS
Cartesian Therapeutics’ mRNA CAR-T therapy met its primary endpoint in a mid-stage trial for the chronic autoimmune disorder and expects to raise $130 million via private placement equity financing.
After forging a partnership last year, Astellas is ending the pact with Cartesian Therapeutics and stopping the development of a Pompe disease candidate.
Boehringer Ingelheim will launch three Phase III studies for its obesity drug candidate; third time is a charm for Ipsen as it gets FDA approval; and Pfizer takes multiple myeloma battle to J&J.
Long-term, opportunities may include using the platform as a vehicle for combination therapies from assets developed by multiple companies.
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
JOBS
IN THE PRESS